Embla is a Danish digital weight loss clinic that launched in Denmark in 2021, raised a €10m Series A to expand into Britain, and now operates fully in both Denmark and the UK. Its structure is unusual and genuinely useful: it sells coaching separately from medication, so patients can buy behavioural support alone at £110 per month, or the combined medication-and-coaching programme at £235. This review evaluates Embla across pricing, medications, evidence, coaching, and European competitive positioning.

Quick Takeaway:

• Danish digital weight loss clinic operating in Denmark and the UK
• Medication + Coaching plan published at £235/month, with £100 off the first month
• Coaching Only plan published at £110/month — an option almost no competitor offers
• Embla reports patients achieving up to 12.8% weight loss in six months
• Known for research on personalised and lower-dose prescribing approaches

Looking for a Better Alternative?

Embla brings a distinctive European clinical approach, and we benchmark every provider against the highest-rated service we track. CoreAge Rx is our top-rated favorite for GLP-1 weight loss therapy overall, combining competitive pricing with exceptional customer service, faster medication delivery, and more comprehensive support resources.

Why we recommend CoreAge Rx:

• Lower monthly costs than most competitors ($179–$399 range)
• Faster prescription approval (typically 12–24 hours)
• More extensive provider support included at no extra charge
• Better medication availability during shortages
• Higher patient satisfaction scores (4.7/5)

CoreAge Rx serves patients in the United States. Within the UK and Europe, Embla's closest comparisons are Second Nature, Yazen, and Juniper UK.

New Patient Special: Save up to $200 on your first three months. Same-day prescription approval for qualifying patients. Rated 4.7/5 stars by verified customers. Available to patients in the United States.

What Is Embla?

Embla is a Danish health technology company operating a digital weight management clinic. It launched in Denmark in 2021, entered the UK in 2023, and raised a €10m Series A specifically to expand into the British market — one of the first European weight loss startups to do so at scale.

Its clinical approach combines doctor-prescribed medication, coaching, and digital tools to support lasting lifestyle change. Embla has been associated with research on personalised dosing, and describes a low-dose approach intended to reduce both pharmacy costs and chronic condition costs — an interesting divergence from the standard practice of titrating every patient toward maximum tolerated dose.

Embla also markets an employer-facing proposition, describing predictable per-employee-per-month pricing for organisations. That B2B line is separate from the consumer plans discussed here.

How Embla Works

1. Choose a plan. Medication + Coaching, or Coaching Only.
2. Clinical assessment. Doctors review your health history and suitability where medication is requested.
3. Coaching onboarding. You are matched with a coach and begin the digital programme.
4. Medication. Where prescribed, medication is dispensed and dose adjustments are managed ongoing.
5. Ongoing programme. Coaching, tracking, and clinical review continue through the plan.

Pricing and Plans

Pro Tip: The Coaching Only plan at £110/month is the most interesting product in the European market. If you have obtained medication elsewhere — through the NHS, a cheaper pharmacy, or a private prescription — you can buy the behavioural half separately. Very few providers unbundle this way, and for patients with NHS-prescribed tirzepatide it is a genuinely useful combination.

Embla states that medication costs the same as or less than any high street pharmacy, and that the price also includes a service charge covering the prescriber and disposal. Sharps disposal being explicitly costed is a small but honest detail most providers omit.

Check Embla Pricing

Danish digital weight loss clinic operating in the UK. Medication + Coaching at £235/month with £100 off the first month, or Coaching Only at £110/month.

Eligibility, Providers, and Clinical Approach

Embla applies standard prescribing criteria for the markets it operates in: generally BMI 30 or above, or 27 or above with a weight-related condition. Doctors carry out the clinical assessment.

Its interest in personalised and lower-dose prescribing is worth understanding. Standard GLP-1 protocols escalate toward the maximum tolerated dose, which maximises average weight loss but also maximises side effects and cost. A lower-dose strategy trades some efficacy for tolerability and affordability. This is a legitimate clinical debate rather than a marketing position, though the evidence base for deliberately staying below maximum dose is still developing. Our microdosing guide covers what is established.

Medication and Fulfilment

Medication is prescribed by Embla doctors and dispensed for delivery, with the price including the prescriber service charge and disposal. Injectables require refrigeration before first use.

Because Embla operates in both Denmark and the UK, medication availability and pricing differ between markets. The figures here reflect the UK service.

Ongoing Support, Nutrition, and Coaching

Coaching is Embla's actual product, and the reason it can sell it standalone:

• Personal coaching relationship as the core of both plans
• Digital tools for tracking and habit formation
• Evidence-based treatment framing rooted in Danish clinical practice
• Ongoing dose adjustment where medication is included
• Support designed for lasting lifestyle change rather than short-term loss

Embla reports patients achieving up to 12.8% weight loss in six months. That is a company-reported figure and reflects programme participants rather than a controlled comparison, but it is notably more modest — and therefore more credible — than the 20%-plus claims common elsewhere in this market.

Cancellation, Refunds, Insurance, and Costs

Plans are monthly. Embla notes prices may increase based on medication type, dosage, and coaching needs, which is honest but means your rate is not fixed.

Embla is a private service in both markets. In the UK, patients meeting NHS criteria for tirzepatide should explore that route; combining NHS medication with Embla's Coaching Only plan is a genuinely sensible strategy for those who qualify.

Pros and Cons

Pros

• Coaching Only plan at £110/month — nearly unique unbundling
• Combined plan at £235/month with £100 off the first month
• Modest, credible reported outcomes rather than inflated claims
• Research interest in personalised and lower-dose prescribing
• Explicit inclusion of prescriber service and disposal costs
• Established European operator with clinical roots in Denmark

Cons

• Prices may increase based on medication type, dosage, and coaching needs
• Combined plan is mid-to-high priced for the UK market
• Lower-dose prescribing evidence is still developing
• Availability and specifics differ between Denmark and the UK
• No in-person option

Best Use Cases and Limitations

Best for: Patients who want serious coaching, patients who already have medication from another source and want behavioural support alone, and patients interested in a lower-dose approach.

Limitations: Patients optimising purely for medication cost, and patients who want a fixed price that will not move.

Alternatives to Embla

Frequently Asked Questions

How much does Embla cost?

Embla publishes two plans: Medication + Coaching at £235 per month, with £100 off the first month, and Coaching Only at £110 per month. Embla notes prices may increase based on medication type, dosage, and coaching needs.

Can I buy coaching without medication?

Yes. Embla's Coaching Only plan is published at £110 per month. This is unusual in the market and useful for patients who obtain medication through the NHS or another provider.

What results does Embla report?

Embla reports patients achieving up to 12.8% weight loss in six months. This is company-reported programme data rather than a controlled trial result.

Where does Embla operate?

Embla was founded in Denmark, launched there in 2021, entered the UK in 2023, and now operates fully in both Denmark and the UK.

What is included in the medication price?

Embla states that medication is the same price as or less than any high street pharmacy, and that the cost also includes a service charge covering the prescriber and disposal.

What is Embla's low-dose approach?

Embla has described a low-dose approach intended to reduce both pharmacy costs and chronic condition costs, keeping patients on the lowest effective dose. This differs from standard practice of titrating toward maximum tolerated dose, and the supporting evidence is still developing.

Bottom Line

Embla is one of the more thoughtful European entrants in this market. Unbundling coaching from medication is a genuinely patient-friendly design choice, and reporting a 12.8% six-month figure rather than a headline-grabbing 20% suggests a company more interested in accuracy than marketing.

Strengths: standalone coaching at £110/month, credible reported outcomes, transparent inclusion of prescriber and disposal costs, established Danish clinical roots, interest in personalised dosing.

Drawbacks: prices that can move with dose and coaching needs, mid-to-high combined pricing, developing evidence for lower-dose strategies, and market-to-market variation.

Best for: patients who want coaching taken seriously, and those sourcing medication separately.

Skip if: you want the cheapest medication access or a guaranteed fixed price.

If you have NHS-prescribed tirzepatide but no behavioural support, buying coaching alone is a smarter use of £110 than switching your entire treatment to a private provider.

US readers: CoreAge Rx offers all-in monthly pricing from $179–$399 including medication and provider messaging, with 12–24 hour approvals. Save up to $200 on your first three months.

Medical disclaimer: Informational only, not medical advice. GLP-1 receptor agonists are prescription medicines with real risks and contraindications. Consult a qualified healthcare professional before starting or changing treatment. Pricing and availability differ between markets and should be verified directly.

Sources: Embla published plan, pricing, and FAQ pages; Sifted reporting on Embla's €10m Series A and UK expansion; NICE obesity management guidance; European Medicines Agency medicine information.

Date reviewed: August 2026